Merck & Co. (MRK) FY2024 10-K Annual Report
Merck & Co. (MRK) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Merck & Co. FY2024 10-K Analysis
Business Overview
- • Core business model: Global pharmaceutical company focused on innovative drug discovery, development, manufacturing, and commercialization
- • New emphasis on immuno-oncology and ophthalmology: Acquisitions/license agreements for MK-2010 (bispecific PD-1/VEGF antibody), MK-4082 (oral GLP-1 receptor agonist), MK-1045 (bispecific antibody for B-cell diseases), EyeBio ($1.2B acquisition, MK-3000 tri-specific antibody), Harpoon ($765M immunotherapy acquisition)
- • Strategic expansion through asset acquisitions in bispecific antibodies and T-cell engagers, enhancing oncology and ophthalmology pipeline engagement
- • R&D expenses charges totaling approx. $3.46 billion in 2024 linked to major acquisitions and licenses, notably $1.35B for EyeBio acquisition and $750M for MK-1045 acquisition
- • Capital expenditures $3.4B in 2024 with $20B planned 2024–2028, including $11B U.S. investments to expand oncology, vaccine, and animal health manufacturing capacity
Management Discussion & Analysis
- • Revenue $64.2B in 2024, up 7% YoY ($60.1B in 2023), or 10% excluding foreign exchange impact
- • Operating segments: Pharmaceutical (not quantified separately) and Animal Health (contributed to growth)
- • Oncology led growth: Keytruda sales $29.5B (+18% YoY, +22% ex-FX), Lynparza alliance revenue $1.3B (+9%), Welireg sales $509M (>100%)
- • U.S. sales $32.3B (+13%), International sales $31.9B (+1%, +6% ex-FX); FX headwind from Argentine peso devaluation
- • Capital returned to shareholders $9.1B: $7.8B dividends, $1.3B buybacks; new $10B share repurchase authorized in Jan 2025
- • Quarterly dividend raised to $0.81 per share from $0.77 in Nov 2024
- • Management highlights pipeline expansion, new product launches Winrevair and Capvaxive, and business development acquisitions
- • Pricing pressures from U.S. healthcare reforms and Inflation Reduction Act with expected negative impact on future pricing and profits
Risk Factors
- • U.S. and international patent disputes threaten market exclusivity for key products impacting revenue protections
- • Significant sales decline expected for Gardasil/Gardasil 9 vaccine in China in 2025 following lower 2024 sales
- • Manufacturing delays for certain products, including vaccines, disrupt supply and could impact revenue streams
- • Intense competition from lower-cost generic and biosimilar products pressures pricing and market share
- • Increasing cyber-attacks on sophisticated software and cloud infrastructure risking disruption of global operations
Merck & Co. FY2024 Key Financial MetricsXBRL
Revenue
$64.2B
▲ +6.7% YoY
Net Income
$17.1B
▲ +4589.6% YoY
Net Margin
26.7%
▲ +2607bp YoY
ROE
37.0%
▲ +3599bp YoY
Total Assets
$117.1B
▲ +9.8% YoY
EPS (Diluted)
$6.74
▲ +4714.3% YoY
Operating Cash Flow
$21.5B
▲ +65.1% YoY
Source: XBRL data from Merck & Co. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Merck & Co. Annual Reports
Get deeper insights on Merck & Co.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.